the applicant has now demonstrated that the administration of sulbutiamine allows recovery from psychomotor and psycho - intellectual disorders described in the first paragraph , in parkinson &# 39 ; s patients , deficient schizophrenics , alcoholics hospitalized for subsequent cure of alcohol deprival , dysthymic patients or alternatively patients suffering major depressive episodes . in the different studies conducted on these patients , sulbutiamine has in every case allowed psychomotor slowing , inhibition of action , intellectual strategy disorders as well as executive function disorders to be avoided . the pharmaceutical compositions used according to the invention contain sulbutiamine , alone or in combination with one or more inert , nontoxic , pharmaceutically acceptable vehicles . the medicaments intended for the treatment of psychomotor and intellectual disorders in these subjects , obtained using sulbutiamine according to the invention , will be present in the form of pharmaceuticals suitable for administration by the oral , parenteral , transcutaneous , nasal , rectal or perlingual route , especially tablets , sublingual tablets , glossettes , gelatin capsules , capsules , tablets , suppositories , transdermal patches , buccal patches , etc . . . the dosage varies according to the age and the weight of the patient , the administration route , the nature of the therapeutic indication and of the associated treatments , and ranges from 400 mg to 800 mg per day orally . effects of sulbutiamine on the psycho - cognitive evolution of alcohol - dependent and deprived patients the study was carried out on a population of hospitalized alcohol - dependent patients after a deprival cure . these patients were divided into two parallel groups and were treated under double - blind conditions for 6 weeks , either with sulbutiamine , or with a placebo , the treatments being allocated according to a randomization code . we evaluated , with the aid of the following tests , the effects of the treatment on : in these alcohol - dependent and deprived patients , treated with sulbutiamine , an improvement of the cognitive and mnesic functions and the attention was observed . effects of sulbutiamine on cognitive slowing , objective and subjective , and on the feeling of fatigue of parkinson &# 39 ; s patients the study was carried out on a population of patients having idiopathic parkinson &# 39 ; s disease , treated by l - dopa and / or dopaminergic agonists , stable on entry into the study , without major fluctuations of the motor state and without signs of dementia . these patients were divided into 2 parallel groups and were treated under double - blind conditions for 8 weeks , either with sulbutiamine , or with a placebo , the treatments being allocated according to a randomization code . by means of the following tests , we evaluated the effects of the treatment on : 1 - the cognitive functions , attention , verbal , ideational and motor slowing : in parkinson &# 39 ; s patients , treated with sulbutiamine , an improvement in the cognitive , executive and mnesic functions was observed , with diminution of the sensation of fatigue . the study was carried out in unhospitalized dysthymic patients having a motor , ideational and cognitive inhibition and slowing . these patients were divided into two parallel groups and treated under double - blind conditions for 8 weeks , either with sulbutiamine , or with a placebo , the treatments being allocated according to a randomization code . a net diminution of the motor , verbal and cognitive slowing in dysthymic patients treated with sulbutiamine was observed . effects of sulbutiamine on inhibition symptoms of major depressive patients treated with a tricyclic antidepressant the study was carried out in patients hospitalized for a major depressive state and treated with clomipramine in a variable dose . these patients were divided into 2 parallel groups and treated for 8 weeks , either with sulbutiamine , or with a placebo , the treatments being allocated according to a randomization code . an improvement in the inhibition symptoms was observed in the group treated with sulbutiamine , in particular of the cognitive functions . effects of sulbutiamine on inhibition symptoms of deficient schizophrenics treated with a neuroleptic the study was carried out on deficient schizophrenic patients treated as outpatients with a neuroleptic . these patients were divided into two parallel groups , then treated under double - blind conditions for 12 weeks , either with sulbutiamine , or with a placebo , the treatments being allocated according to a randomization code . a regression of the signs of schizophrenia was observed in the group treated with sulbutiamine , with an improvement in the quality of life in parallel .
the invention relates to the use of sulbutiamine and pharmaceutical compositions thereof for the treatment of parkinson &# 39 ; s disease , schizophrenia , alcoholism , and dysthymia .